Stocks in Focus

WOOREE BIO CO., LTD Rises for Second Consecutive Day Following Stock Split… Up 7% After Hitting Daily Price Limit the Previous Day [Featured Stock]

Shin Ha-yeon
2026-09-08 09:10:50
[Edaily Reporter Shin Ha-yeon ] WOOREE BIO CO., LTD(082850)continues its upward trend for the second consecutive day following its relisting after a stock split.

According to MP Doctor on the 8th, as of 9:09 a.m., WOOREE BIO CO., LTD is trading at 6,250 won, up 7.20% from the previous trading day. During the session, the stock rose as high as 6,920 won.
[This image was created using AI technology.]

On the previous day, WOOREE BIO CO., LTD completed its relisting following a stock split and resumed trading; on the first day of trading, the stock rose to the daily price limit and closed at 5,830 won.

The company consolidated five common shares into one, and as a result, trading was temporarily suspended for the re-listing of the revised shares before resuming the previous day.

While a stock split does not alter a company’s intrinsic value, it reduces the number of shares outstanding and adjusts the stock price unit. Following the resumption of trading, strong buying interest has continued into the early trading session today, building on yesterday’s price limit-up performance.

Economy

Corporation

IT·Science

Economy

Shifting from Short-Term to Medium- and Long-Term... Appeal of Commercial Paper as a Funding Source Plummets

Fluctuations in credit spreads serve as an indicator of investor sentiment and capital flows in the corporate bond market. “Credit Signal” provides an intuitive analysis of the market’s overall trends…
2026-10-23 17:57:04

Corporation

Jeong Yong-jin Starts by Replacing E-MART Co., Ltd.’s CEO… Appoints Entire Executive Team in Their 40s

Shinsegae Co.,Ltd Chairman Chung Yong-jin is returning to the forefront of management at E-MART Co., Ltd.(139480). Unlike in 2013, when he stepped down as a registered director and entrusted the busin…
2026-10-23 14:55:06

IT·Science

FutureChem Co., Ltd. Releases Results of U.S. Phase 2a Trial for Prostate Cancer Treatment… Tumors Shrunk in 7 of 18 Patients

FutureChem Co., Ltd.(220100)announced on the 23rd the topline results of the U.S. Phase 2a clinical trial for its prostate cancer drug candidate “FC705.” Among the 18 patients with measurable lesions,…
2026-10-23 17:50:02